Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
REGULATORY
MHLW Orders Label Revisions for NSAIDs, Salbutamol, Kymriah
The Ministry of Health, Labor and Welfare (MHLW) ordered on February 25 the revision of package inserts for a slew of non-steroidal anti-inflammatory drugs (NSAIDs) not contraindicated in pregnant women to warn of the risk of possible side effects in…
To read the full story
Related Article
- PMDA Reviewing Safety Risks for NSAIDs, and More Products
February 1, 2021
REGULATORY
- MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
- Honebuto Outline Includes “Raise in Official Prices,” but Details Yet Unknown
May 27, 2025
- Japan Govt Plans Consortium for Driving Domestic Production of Radioisotopes
May 27, 2025
- Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
May 27, 2025
- MSD’s Welireg, BMS’ Inrebic, J&J’s Talvey Up for Japan Panel Review on June 6
May 26, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…